{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:43Z","timestamp":1787071663834,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"\n Purpose:<\/jats:title>\n To evaluate the efficacy of povidone-iodine 1.0% and dexamethasone 0.08% combination eye drops in treating post-viral corneal subepithelial infiltrates (SEIs).<\/jats:p>\n <\/jats:sec>\n \n Design:<\/jats:title>\n This was a prospective, randomized comparative study of adult patients with SEIs. Patients were randomly assigned to three groups: Group 1 received combined povidone-iodine and dexamethasone eye drops with lubricating eye drops; Group 2 received dexamethasone and lubricating eye drops; Group 3 received povidone-iodine and lubricating eye drops. Treatment lasted for two weeks.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients aged 18 years or older with SEIs of 1\u20136 months duration were included. One eye per patient was chosen for treatment. If both eyes were affected, the eye with the more severe presentation was selected. Exclusion criteria included thyroid disease, allergy to study medications, ocular surgery within the last three months, and other conditions like corneal ulceration or active conjunctivitis. Patients were evaluated at baseline, 2 weeks, 6 weeks, and 6 months post-treatment for best-corrected visual acuity (BCVA), intraocular pressure, symptoms, and modified Corneal Subepithelial Infiltrates Score (modified CSIS).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 45 eyes (15 per group) were included. The combination treatment significantly improved BCVA (\n P<\/jats:italic>\n < 0.001), symptoms (\n P<\/jats:italic>\n = 0.020), modified CSIS (\n P<\/jats:italic>\n < 0.001), and reduced recurrence (\n P<\/jats:italic>\n < 0.001) compared to the other two groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Combined povidone-iodine 1% and dexamethasone 0.08% eye drops offer superior improvement in SEIs, BCVA, and symptom relief, with lower recurrence compared to individual treatments. These findings suggest a potential synergistic effect of combined treatment in managing SEIs.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_3090_24","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:00:38Z","timestamp":1758801638000},"page":"1477-1481","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy of combined povidone-iodine 1% and dexamethasone 0.08% prepared eye drops in treating post-viral corneal subepithelial infiltrates"],"prefix":"10.4103","volume":"73","author":[{"given":"Mowaffaq K","family":"Alkassasbeh","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz H","family":"Alzweimel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A","family":"Alshdaifat","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M","family":"Alkilany","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A","family":"Alhassan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa K","family":"Khlaifat","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed B","family":"Nawaiseh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/09273948.2010.498658","article-title":"Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis","volume":"18","author":"Chintakuntlawar","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/IDR.S162669","article-title":"Pathogenesis and management of adenoviral keratoconjunctivitis","author":"Chigbu","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QCO.0000000000000451","article-title":"Human adenovirus infections: Update and consideration of mechanisms of viral persistence","volume":"31","author":"Radke","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1167\/iovs.10-5944","article-title":"Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis","volume":"52","author":"Clement","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/aos.13416","article-title":"Treatment of adenoviral keratoconjunctivitis with a combination of povidone\u2010iodine 1.0% and dexamethasone 0.1% drops: A clinical prospective controlled randomized study","volume":"95","author":"Kovalyuk","year":"2017","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"101873","DOI":"10.1016\/j.clae.2023.101873","article-title":"A systematic review and meta-analysis on the efficacy of topical povidone iodine in adenoviral conjunctivitis","volume":"46","author":"Mart\u00edn-Moro","year":"2023","journal-title":"Contact Lens Anterior Eye"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ajo.2019.02.039","article-title":"Randomized, controlled, phase 2 trial of povidone-iodine\/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis","volume":"205","author":"Pepose","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/OPX.0000000000001091","article-title":"Effect of povidone iodine 5% on the cornea, vision, and subjective comfort","volume":"94","author":"Ridder","year":"2017","journal-title":"Optom Vis Sci"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jop.2011.0082","article-title":"Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: A pilot study","volume":"28","author":"Trinavarat","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.18240\/ijo.2019.09.08","article-title":"Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates","volume":"12","author":"Altan-Yaycioglu","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4103\/ijo.IJO_1352_18","article-title":"Comparison of the safety and efficacy of topical tacrolimus (0.03%) versus dexamethasone (0.05%) for SEIs after adenoviral conjunctivitis","volume":"67","author":"Bhargava","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/ICO.0000000000002589","article-title":"Corticosteroids versus cyclosporine for subepithelial infiltrates secondary to epidemic keratoconjunctivitis: A prospective randomized double-blind study","volume":"40","author":"Gouider","year":"2021","journal-title":"Cornea"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/bjo.2010.188623","article-title":"A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis","volume":"95","author":"Wilkins","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00003226-199305000-00006","article-title":"A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis","volume":"12","author":"Ward","year":"1993","journal-title":"Cornea"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/eye.2017.4","article-title":"Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis","volume":"31","author":"Asena","year":"2017","journal-title":"Eye"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","article-title":"The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: A controlled clinical pilot study","volume":"109","author":"Hillenkamp","year":"2002","journal-title":"Ophthalmology"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10792-016-0260-1","article-title":"Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection","volume":"37","author":"Ozen","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R18-20260420","first-page":"100","article-title":"Ganciclovir in the treatment of ophthalmic viral infections-case reports","volume":"5","author":"Affeldt","year":"2012","journal-title":"J-Ganciclovir Treat Ophthalmic Viral Infect Rep"},{"key":"R19-20260420","first-page":"315","article-title":"Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods","author":"Huang","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0002-9394(76)90017-9","article-title":"Use of vidarabine in epidemic keratoconjunctivitis due to adenovirus types 3, 7, 8, and 19","volume":"82","author":"GO","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/archopht.116.7.900","article-title":"The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication","volume":"116","author":"Gordon","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/ICO.0b013e3181c33034","article-title":"Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis","volume":"29","author":"Levinger","year":"2010","journal-title":"Cornea"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ico.0000127481.23714.b6","article-title":"Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models","volume":"24","author":"Romanowski","year":"2005","journal-title":"Cornea"},{"key":"R24-20260420","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/ICO.0b013e31820cd607","article-title":"Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis","volume":"30","author":"Jeng","year":"2011","journal-title":"Cornea"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-12-42","article-title":"Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis","volume":"12","author":"Okumus","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"R26-20260420","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00417-014-2611-9","article-title":"Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis","volume":"252","author":"Levinger","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R27-20260420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajo.2010.07.028","article-title":"Phototherapeutic keratectomy for the treatment of corneal opacities after epidemic keratoconjunctivitis","volume":"151","author":"Yamazaki","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R28-20260420","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2415-12-42","article-title":"Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis","volume":"12","author":"Okumus","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"R29-20260420","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2353\/ajpath.2007.070172","article-title":"Dexamethasone inhibits interleukin-1\u03b2-induced corneal neovascularization: Role of nuclear factor-\u03baB-activated stromal cells in inflammatory angiogenesis","volume":"171","author":"Nakao","year":"2007","journal-title":"Am J Pathol"},{"key":"R30-20260420","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/tjo.tjo_66_19","article-title":"A treatment protocol for minimizing duration and complications of adenoviral epidemic keratoconjunctivitis","volume":"10","author":"Kulkarni","year":"2020","journal-title":"Taiwan J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3090_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:40Z","timestamp":1787068240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3090_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3090_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2024-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}